Bipolar dysfunction presents a singular problem for sufferers and clinicians in medication, because it entails managing two utterly completely different shows of the identical sickness, each by way of therapy and stopping relapse. Totally different therapy choices are additionally not equally efficient in both treating or stopping episodes of mania or melancholy.
Subsequently, within the first episode of mania in bipolar dysfunction, the query clinicians face isn’t solely “how can I deal with this particular person and get them higher as rapidly as doable?”, but additionally find out how to stop future relapses. Tips akin to NICE (NICE, 2014) and British Affiliation of Psychopharmacology (Goodwin et al 2016) recommend utilizing a second-generation antipsychotic (SGA) as a primary possibility and including a temper stabiliser if this isn’t efficient. For sufferers who do reply properly with SGAs and recuperate, clinicians and sufferers are confronted with a call concerning long-term therapy for relapse prevention: do I persist with the present antipsychotic treatment which has led to restoration, or do I swap or add a temper stabiliser for relapse prevention?
As SGAs are additionally an possibility for relapse prevention, it appears many are selecting to ‘stick’, reasonably than threat a swap with new treatment with unknown efficacy and negative effects from a person perspective. As earlier elves have famous, the usage of lithium is declining (Edward & Ahmed 2019) although it stays the simplest treatment in stopping depressive relapses in bipolar dysfunction (Swiffen 2025).
The current paper by Szmulewicz et al (2026) used observational information to check the chance of relapse between these on temper stabiliser monotherapy, SGA monotherapy and mixture remedy of a temper stabiliser and SGA.
Strategies
The researchers used information from digital well being data of sufferers handled inside first episode psychosis providers and explicitly emulated a ‘goal trial’, i.e. said how a hypothetical randomised managed trial (RCT) would reply their analysis query.
On this case, the goal trial was assessing whether or not temper stabilisers alone, SGAs alone or a mixture of each had been higher at stopping relapse (outlined as hospitalisation or emergency division attendance because of any psychiatric motive) in sufferers with bipolar dysfunction who had been handled for mania with psychotic signs. Members had been aged over 16 years had been included from a number of first episode psychosis cohorts in North America, Chile and Spain. Sufferers had been included in the event that they hadn’t been taking antipsychotics or temper stabilisers over the earlier 3 months and had been categorised as being began on both SGAs (Olanzapine, Risperidone, Aripiprazole or Quetiapine), temper stabilisers (Lithium or Valproic Acid) or mixture remedy.
The examine adopted individuals as much as 2 years, or till relapse or loss to observe up. In addition to general relapse they checked out manic/combined relapse, and depressive relapse/suicide-related occasion as secondary outcomes. Over the two-year interval, particular person individuals might be eligible for a number of “trials” e.g. in the event that they had been on a temper stabiliser, then discontinued for greater than 3 months, after which commenced an antipsychotic.
The examine used each intention-to-treat (based on assigned therapy) and per protocol (based on adherence to therapy) analyses. Sensitivity analyses had been carried out to analyse a variety of various doable situations that might have affected the outcomes.
Outcomes
There have been 371 eligible individuals with first episode psychotic mania that corresponded to 465 therapy initiations (as some individuals contributed a couple of “trial” in the course of the observe up). There have been 112 temper stabiliser monotherapy initiations (in 79 particular person sufferers), 167 second-generation antipsychotic monotherapy initiations (in 108 particular person sufferers), and 186 mixture remedy initiations (in 184 particular person sufferers).
The median observe up was 19.8 months and throughout the entire cohort 42% had a relapse, 35% had been misplaced to observe up and 4% had a change of prognosis.
After adjusting for baseline variations (together with demographics, baseline severity, substance use dysfunction, earlier episodes or admissions, earlier treatment use) the 2-year threat of relapse was:
- 42.3% for temper stabiliser monotherapy,
- 49.5% for SGA monotherapy and
- 42.2% for mixture remedy.
Head-to-head comparisons of confirmed a threat discount of -7.3% (-15·8 to -1·4) for temper stabilisers in comparison with SGA monotherapy, and -7.4% (-16·0 to -2·1) for mixture remedy in contrast with SGA monotherapy. Primarily which means that the chance of relapse was very related between temper stabiliser monotherapy and mixture teams, which had been each about 7 proportion factors decrease than the SGA monotherapy group.
The outcomes had been related within the per-protocol evaluation which took under consideration therapy adherence. After adjusting for related confounders, the 2-year threat of relapse was 38·9% for temper stabiliser monotherapy, 46·8% for SGA monotherapy and 38·4% for mixture remedy. Head-to-head comparisons confirmed a -7·9% (-13·9 to 0·5) threat discount for temper stabilisers in comparison with SGA monotherapy, and -8·4% (-15·4 to -0·8) for mixture remedy in contrast with SGA monotherapy. These outcomes had been just like the intention-to-treat evaluation, although the boldness intervals evaluating temper stabilisers to SGA monotherapy included zero, which suggests a much less vital distinction between these teams.
In secondary evaluation the chance of manic or combined relapses was very related throughout teams, however the threat of depressive relapse was decrease in both the temper stabiliser monotherapy -5·2% (-11·1 to -0·1) or mixture remedy -7·0% (-12·1 to -1·9) teams in comparison with SGA monotherapy.
Conclusions
Subsequently, relapse charges had been decrease in these receiving temper stabilisers alone or together with antipsychotics, in comparison with SGAs alone. This implies that in first episode mania with psychosis, a therapy technique ought to embody a temper stabiliser to stop relapse, both alone or together with an SGA.
Strengths and limitations
This cohort examine which emulated a ‘goal trial’ is a well-designed, essential examine which contributes to our understanding of how remedies may scale back relapse following first episode psychotic mania. The authors acknowledge that the best examine to reply this query could be an precise RCT (versus an emulation of 1), however there are sensible difficulties by way of the set-up, retention and funding for these. The authors have explicitly outlined the goal trial, used strong evaluation to account for quite a lot of potential confounders and sensitivity evaluation of a variety of different situations, which provides additional weight to their findings.
Nonetheless, a problem with all observational research is the chance of uncontrolled confounding when a variable that influences each the publicity and the end result is left unmeasured or unadjusted. Right here there might have been elements that might have affected the selection of therapy and had been linked to the end result, regardless of changes within the evaluation. There was greater baseline severity within the group began on SGA monotherapy, and likewise a better proportion of antidepressants prescribed on this group, although these had been adjusted for within the evaluation. The authors acknowledge different potential unmeasured confounders, akin to persona traits, household historical past, in addition to threat profile which may have affected therapy selections and outcomes. That stated, the examine design evaluating three teams offers some additional weight to their findings, as logically chances are you’ll count on these with larger threat of relapse or poor preliminary response to be on mixture remedy, which had related outcomes to the temper stabiliser group, however considerably decrease relapse charges than the SGA monotherapy group.
It’s price contemplating that medicines used within the examine had been grouped as ‘temper stabilisers’ or ‘SGAs’ because of pattern dimension issues. Lithium was probably the most generally used temper stabiliser and the SGAs used had been Olanzapine, Risperidone, Aripiprazole and Quetiapine, with Olanzapine and Risperidone used most steadily. There may be proof of variations amongst antipsychotics in stopping depressive relapses with Quetiapine exhibiting higher proof in comparison with Risperidone and Aripiprazole (Kishi et al 2021), which may have affected the outcomes.
Lastly, the examine didn’t assess adversarial results of medicines or explicitly report discontinuation because of adversarial results. Uncomfortable side effects are a serious consideration within the alternative of prescribing long-term remedies for relapse prevention and subsequently make up a substantial a part of the session and decision-making course of in scientific follow.
Implications for follow
This examine demonstrates in an actual world setting that temper stabilisers, both alone or together with SGAs, might scale back relapse charges following first episode psychotic mania in comparison with SGAs alone. Although the examine was not randomised, it was a well-designed cohort examine which emulated a goal trial. Furthermore, at the side of present proof it offers additional weight to the discovering that temper stabilisers, specifically lithium, are preferable for stopping relapse in sufferers with bipolar dysfunction.
Future research ought to verify these findings with well-designed randomised research. Ideally completely different temper stabilisers (e.g. lithium and valproate), and completely different SGAs needs to be in comparison with decide if there are variations with particular medicines. Research that look at adversarial results and discontinuation in a real-world setting would additionally assist clinicians and sufferers of their choice making.
The examine helps so as to add additional proof to reply the scientific query for a lot of sufferers with bipolar dysfunction: when a manic episode has been efficiently handled with antipsychotics, in an effort to stop relapse, ought to I stick or twist? Many sufferers and clinicians seem reluctant to modify, which can have led to the declining use of lithium and improve of SGA use in bipolar dysfunction. This can be because of considerations about negative effects, monitoring necessities, or just uncertainty as to what further profit could be achieved by switching. Sufferers might usually really feel they’re managing properly with their preliminary SGA, and subsequently are reluctant to ‘rock the boat’ or change one thing that seems to be working.
Szmulewicz et al’s findings recommend that beginning with a temper stabiliser might provide a greater different, significantly for decreasing the chance of depressive relapse, which is usually probably the most difficult and disabling temper part of bipolar dysfunction for sufferers. With the ability to present clinicians with this data will hopefully result in a extra knowledgeable dialogue with sufferers about whether or not to ‘stick or twist’.
Assertion of pursuits
Tobias Rowland has no conflicts of curiosity to declare. All intelligence used within the writing of this weblog was strictly non-artificial.
Editor
Simon Bradstreet.
Hyperlinks
Main paper
Alejandro Szmulewicz, Yu-Hsin Liang, Gonzalo Martínez-Alés, Ryan O’Dea, Lorna Thorpe, Sarah Conderino, José Rubio, Kerry Smith, Deepak Sarpal, Covadonga Díaz-Caneja, Celso Arango, Paul Vöhringer, Sophia Aldunate, Ridha Joober, Jai Shah, Ashok Malla, Diane Fredrikson, Lakshmi Yatham, Miguel Hernán, Dost Öngür (on behalf of the BD-CAUSAL Collaboration) (2026). Comparative effectiveness of temper stabiliser monotherapy versus second-generation antipsychotic monotherapy versus mixture remedy for continuation and upkeep therapy after a primary episode of psychotic mania in North America, Chile, and Spain: a goal trial emulation utilizing information from the BD-CAUSAL Collaboration. The Lancet Psychiatry, 13, 861-869
Different references
Goodwin GM., Haddad PM., Ferrier IN. et al (2016). Proof-based pointers for treating bipolar dysfunction: Revised third version suggestions from the British Affiliation for Psychopharmacology. Journal of Psychopharmacology 2016, Vol. 30(6) 495 –553.
Kishi, T., Ikuta, T., Matsuda, Y. et al (2021). Temper stabilizers and/or antipsychotics for bipolar dysfunction within the upkeep part: a scientific evaluate and community meta-analysis of randomized managed trials. Molecular Psychiatry 26, 4146–4157 (2021).
NICE (2014). Bipolar dysfunction: Evaluation and Administration | Steerage | NICE. Nationwide Institute for Well being and Care Excellence.
